The PennZone

  • Home
  • Business
  • Health
  • Education
  • Construction
  • Financial
  • Legal
  • Entertainment
  • Music

OncoBeta GmbH and Australian Nuclear Science and Technology Organisation sign Letter of Intent to establish manufacturing site in Australia
The PennZone/10084426

Trending...
  • New Release: 'The Invisible Alternative' Unveiled by Atrisk Corporation, Resilient
  • From Real Estate to Reel Power: H.L Woods Carves His Legacy as a Cutting-Edge Visionary Filmmaker
  • SacraPod Suites Unveils AI-Powered 'Work + Rest' Smart Hospitality Model for Retrofitting Underused Motels Across the U.S
Rhenium Sct Produced In Australia Capture Obg Press Photo 1 No Language 002 OncoBeta GmbH
Innovative medical device Rhenium-SCT® therapy for non-melanoma skin cancer to be produced in Australia

MUNICH - PennZone -- Garching n. Munich, Germany and Lucas Heights, NSW, Australia – OncoBeta® GmbH, a commercial stage medical device company specialized in innovative epidermal radioisotope therapies for non-melanoma skin cancers and the Australian Nuclear Science and Technology Organisation (ANSTO), are pleased to announce that they have signed a Letter of Intent to establish manufacturing and distribution in Australia for OncoBeta's novel Rhenium-SCT® therapeutic.

ANSTO is the leader in nuclear science in Australia and has extensive experience in the manufacturing of radiopharmaceutical diagnostics, therapies and medical devices, they are the perfect partner for OncoBeta to work with to introduce the Rhenium-SCT® product to Australia. Together, the parties will achieve a key milestone, bringing the production of Rhenium-SCT® closer to Australians suffering of non-melanoma skin cancer. OncoBeta is currently in the process of securing Australian Market Approval for its product.

The global incidence of non-melanoma skin cancers has been drastically increasing over the past decades. It is estimated that there are over 5 million non-melanoma skin cancer cases reported globally each year. Non-melanoma skin cancer is the most common type of cancer in Australia with over 500,000 people each year being diagnosed with one or more of these cancers.

ANSTO General Manager Business Development and Commercialization, Rosanne Robinson stated, "ANSTO is proud to partner with OncoBeta to establish local manufacturing of Rhenium-SCT® and to continue delivering on our core mission of improving the health of Australians and supporting industry. ANSTO has a long-standing relationship with OncoBeta and look foward Australian patients having access to their innovative therapy for non-melanoma skin cancers. OncoBeta will join our growing nandin innovation community, focussed on attracting entrepreneurs, early stage start-ups and innovative companies who want to leverage the opportunity to be co-located with ANSTO and to access our unique expertise in the nuclear industry."

More on The PennZone
  • AI Visibility: The Key to Beating Google's AI Overviews and Regaining Traffic
  • Stuck Doing Math or Figuring Out Life's Numbers? Calculator.now Makes It Stupidly Simple
  • CLASS ACTION REMINDER: Berger Montague Advises Hims & Hers Health Inc. (NYSE: HIMS) Investors to Inquire About a Securities Fraud Lawsuit by August 25, 2025
  • Colbert Packaging Announces WBENC Recognition
  • SHI Cryogenics Group Launches Highest-Capacity Single-Stage Cryocoolers to Date

Nicholas H. Vetter, Chief Operating Officer of OncoBeta® GmbH stated: "We are incredibly excited to start extending our production footprint to Australia. It's a great pleasure to work towards solidifying a partnership with ANSTO so we can do our jobs: to bring the Rhenium-SCT® to large patient populations suffering of non-melanoma skin cancer. With this partnership we can finally move beyond trying to service the market from our other production sites in Europe or South Africa. It's a perfect time to expand our business."

About the Rhenium-SCT® (Skin Cancer Therapy)

The Rhenium-SCT® is a non-invasive, painless therapy generally providing for unparalleled aesthetic results, even in cases otherwise considered difficult to treat. The Rhenium-SCT® utilizes the radioisotope Rhenium-188 in an epidermal application with optimal properties for the treatment of NMSCs (non-melanoma skin cancers). Due to the specially designed devices and accessories the Rhenium-SCT® compound never comes in direct contact with the patients' skin and the application is safe and simple for the applying physician. Most cases of non-melanoma skin cancers (Basal Cell Carcinomas and Squamous Cell Carcinomas) can be treated using the Rhenium-SCT® with a single application, applied in one single session. Scar-free healing of the treated lesion area and the regeneration of healthy tissue occurs usually within a few weeks after treatment.

About ANSTO

ANSTO leverages great science to deliver big outcomes. We partner with a broad range of industry partners to apply new technologies to provide real-world benefits. Our work improves human health, saves lives, builds our industries and protects the environment.  ANSTO is the home of Australia's most significant landmark and national infrastructure for research. Thousands of scientists from industry and academia benefit from gaining access to state-of-the-art instruments every year.

More on The PennZone
  • DivX Empowers Media Enthusiasts with Free Expert Guides for Advanced MP4 Management
  • Federated Hermes Premier Municipal Income Fund declares dividend
  • Assent Expands Executive Team to Accelerate Global Growth & Innovation
  • The World's Largest Green Economic Revolution Emerges as Nature, Tech, and Finance Converge
  • Vinnetwork Unveils Decentralized AI Platform with Vinnetwork(VIN) Token to Challenge Tech Giants' Data Monopoly

For more information visit www.ansto.gov.au

About OncoBeta® GmbH

OncoBeta® GmbH with its headquarters located at the Garching Technology and Founders Center GATE near Munich, is a privately held medical device company, specializing in the development and commercialization of state-of-the-art, innovative therapies utilizing epidermal radioisotope applications. Since its foundation, OncoBeta® GmbH has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting non-melanoma skin cancers. Since then, OncoBeta® has successfully perfected the customized application and device management system in conformity with all health, safety, and environmental protection regulatory standards.

Find out more about the Rhenium-SCT® at www.oncobeta.com

Follow us on social media:

LinkedIn: https://www.linkedin.com/company/oncobeta-gmbh/

Facebook: https://www.facebook.com/oncobeta/

Forward-looking statements

This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OncoBeta's control and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OncoBeta's plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OncoBeta® undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

Contact
OncoBeta GmbH
info@oncobeta.com
+49 (89) 5484224 0


Source: OncoBeta GmbH
Filed Under: Health

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • The Waite Launches: A Curated Motherhood Marketplace For Every Stage
  • Affordable, High-Quality Care: Cheap Braces for Adults Available from Exeter Smiles in Reading
  • NASA Collaborative Agreement for Supply of Thin-Film Solar Tech for Orbital Application to Advance Development of Thin-Film PV Power Beaming: $ASTI
  • Sci-Fi Novel from Pittsburgh Author Explores Love, Power, & Humanity in an Age of Artificial People
  • Exciting New Era of Sports, Entertainment & Gaming Innovation Spotlighted by Rebrand of Expanding AI Driven, Online Fan Engagement Company: SEGG Media
  • Greenlight Networks to Acquire Loop Internet
  • Finding the Best AC Repair Service in Philadelphia
  • Service Ninjas Debuts First-of-Its-Kind "Membership" Platform for Home Service Pros
  • BIYA Forecasts 2025 Surge with ¥300M ($41.8 M USD) in Revenue and ¥25M Profit from Cloud Based HR Solutions: Baiya Intl. Group (N A S D A Q: BIYA)
  • Paul E. Saperstein Co. Announces Geographic Expansion of Auction Services
  • Florida Broker Bent Danholm Featured in the Daily Mail's U.S. Real Estate Coverage
  • Robin Launches Legal Intelligence Platform to solve intelligence gap in Fortune 500 legal teams
  • Melissa B. Releases Digitally Independent: Empowering Music Artists with AI and Brand Strategy
  • Consumer Accountability Alliance Issues Formal Notice Alleging Proximate Liability for Medical Harm
  • Phillie Phanatic Joins the Together We Dance Foundation's Summer Dance Team to Celebrate Inclusion
  • Utah Metal Fabricator Titan Forge Builds Momentum with Custom Steel Projects and Spiral Staircases
  • Jason Koch: Pioneering the Future of Real Estate Development in New Jersey
  • CLASS ACTION NOTICE: Berger Montague Advises Hims & Hers Health Inc. (NYSE: HIMS) Investors to Inquire About a Securities Fraud Class Action
  • e4health Earns 2025-2026 Great Place To Work Certification™ for Fourth Consecutive Year
  • Bach and Beyond: Cellists Return to the Beach for 2nd Annual Bethany Beach Cellofest

Popular on PennZone

  • INVESTIGATION ALERT: Berger Montague PC Investigates Coinbase Global, Inc.'s Board Of Directors For Breach of Fiduciary Duties (NASDAQ: COIN)
  • Innovative EDM Music Project, "Terms of War," Depicts an A.I. Takeover of Earth
  • Kemeny, Ramp & Renaud Expands Legal Team with Attorney Baruch Kraut
  • LIB Continuous Innovation: Custom Rain Test Chambers & IP Labs
  • New Bethany Acquires Former Diocesan Headquarters to Expand Services
  • Bethany Nikitenko Honored By Legal Intelligencer with Power Player Award
  • Continued Streak of Recognitions with Multiple Chambers and Partners Rankings
  • IRF Builders Forum Brings Global Leaders to Washington, D.C. to Advance Religious Freedom Through Cooperative Engagement
  • Edtech Startup Young Commanders Launches 'Visionaries Without Sight' Collection Celebrating Blind and Visually Impaired Historical Figures
  • JOSHWAY Launches Children's Book, "JOSHWAY and the Power of Resilience"

Similar on PennZone

  • Revolutionary Blockchain Platform Okh Finance Announces Okh Finance(OKKH) Token Launch to Transform Global Asset Leasing Market
  • Stuck Doing Math or Figuring Out Life's Numbers? Calculator.now Makes It Stupidly Simple
  • Colbert Packaging Announces WBENC Recognition
  • SHI Cryogenics Group Launches Highest-Capacity Single-Stage Cryocoolers to Date
  • DivX Empowers Media Enthusiasts with Free Expert Guides for Advanced MP4 Management
  • Assent Expands Executive Team to Accelerate Global Growth & Innovation
  • The World's Largest Green Economic Revolution Emerges as Nature, Tech, and Finance Converge
  • Vinnetwork Unveils Decentralized AI Platform with Vinnetwork(VIN) Token to Challenge Tech Giants' Data Monopoly
  • Pyro Marketing Opens New Digital Marketing Company in Saint Petersburg to Power Growth for Fitness and Ecommerce Brands
  • Dr. John Salerno of Salerno Wellness Introduces Their New Full Body Capsule for Advanced LED Light Therapy Patient Treatments
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us